Status:
WITHDRAWN
Ribavirin for Hemorrhagic Fever With Renal Syndrome
Lead Sponsor:
U.S. Army Medical Research and Development Command
Conditions:
Hemorrhagic Fever With Renal Syndrome
Eligibility:
All Genders
17-65 years
Phase:
PHASE2
Brief Summary
Hemorrhagic Fever with Renal Syndrome (HFRS) is caused by a virus acquired by contact with chronically infected rodent hosts. HFRS is present throughout Korea. Treatment consists mainly of supportive ...
Detailed Description
Hemorrhagic Fever with Renal Syndrome (HFRS) is caused by viruses in the genus Hantavirus of the family Bunyaviridae. There are four known Hantavirus that cause HFRS: Hantaan, Seoul, Puumala and Dobra...
Eligibility Criteria
Inclusion
- Have read and signed the Informed Consent (see Exception for Emergency Treatment, Section 12.0).
- Are at least 18 years of age (17, if active military) and not greater than 65 years of age.
- Meet the case definition for a probable or suspected case (see Section 5.0).
- Have a blood sample drawn and a type and cross-match ordered for transfusion.
- Agree to collection of required specimens.
- Agree to report any Adverse Events, Serious and Unexpected Adverse Events for the duration of the study.
- Agree to a follow-up visit and to donate blood and urine specimens at day 10, day 14 and between days 28 and 60 after the first dose of IV Ribavirin and to all follow-up visits for anemia or other medical conditions as required by the attending physician.
- Women of childbearing age must have a negative pregnancy test and agree not to become pregnant for 7 months after receiving Ribavirin. Women will be counseled concerning the risks of IV Ribavirin.
- Men agree not to have intercourse with pregnant women for 7 months after receiving Ribavirin, and take precautions to avoid producing pregnancies for 7 months after receiving Ribavirin.
- Have a hemoglobin greater than or equal to10 g/dL before starting IV Ribavirin.
Exclusion
- A known intolerance to Ribavirin.
- Are irreversibly ill on presentation, as defined by presence of profound shock, which does not respond to supportive therapy within 3 hours after admission.
- A positive pregnancy test.
- An estimated creatinine clearance \< 20 ml/minute.
- A history of hemoglobinopathies (i.e., sickle-cell anemia or thalassemia major).
- A history of autoimmune hepatitis.
- A hemoglobin less than 10 g/dL that cannot be corrected to ≥10 g/dL before initiation of IV Ribavirin.
- A New York Heart Association Cardiac functional capacity of Class II or greater for ASHD and CHF.
- Known cardiac conduction defects that may predispose the subject to arrhythmias, such as second or third degree heart block or sick sinus syndrome (and no pacemaker), or Wolfe-Parkinson-White Syndrome.
- A sinus bradycardia of less than 40 beats per minute (or sinus bradycardia less than 50 beats per minute if the individual is not known to have a low resting heart rate related to physical conditioning).
- Concurrent therapy with Didanosine (ddI). DdI must be discontinued before starting the IV Ribavirin.
- Relative
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00623168
Start Date
February 1 2008
End Date
December 1 2019
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brian Allgood Army Community Hospital (121st Combat Support)
Seoul, South Korea